The new positive data from the Phase I trial of TG6002 show in all patients that this oncolytic virus, administered intravenously, is capable of reaching the tumor, multiplying there and expressing its armament.
Strasbourg, France, September 12, 2022, 8 a.m. – Transgene (Euronext Paris: TNG), a biotechnology company that designs and develops immunotherapies based on viral vectors against cancers, announces new positive data from the Phase I trial combining intravenous (IV) administration of the oncolytic virus TG6002 and oral intake of 5-FC in patients with advanced gastrointestinal carcinomas.
TG6002 is an oncolytic virus using the VVcopTK-RR- viral strain, which is the foundation of the Invir.IO™ platform. This proprietary technological platform makes it possible to generate numerous multifunctional oncolytic virus candidates.
These new data were generated in 37 patients treated at the highest doses in the Phase I trial. They show that the treatment is well tolerated and confirm the mechanism of action of TG6002 administered IV. These results were presented on September 11, 2022 in a poster at the annual conference of the European Society for Medical Oncology (ESMO), which takes place in Paris from September 9 to 13, 2022.
See press release in PDF for the full text.